Achillion

New Haven, United States Founded: 1998 • Age: 28 yrs Acquired By Alexion
Treatments for Hepatitis C and complement-mediated diseases are developed.
Request Access

About Achillion

Achillion is a company based in New Haven (United States) founded in 1998 was acquired by Alexion in October 2019.. Achillion has raised $41 million across 1 funding round from investors including Alexion, Schroders and GE Capital. Achillion operates in a competitive market with competitors including Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics, among others.

  • Headquarter New Haven, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $41 M (USD)

    in 1 rounds

  • Latest Funding Round
    $41 M (USD), Series C

    Jan 28, 2002

  • Investors
    Alexion

    & 8 more

  • Employee Count
    Employee Count
  • Acquired by
    Alexion

    (Oct 16, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Achillion
Headcount 50-200
Employee Profiles 11
Employee Profiles
People
Susanne Heinzinger
Senior Vice President, Commercial Strategy, Patient Advocacy and Communications
People
Brit Shell
Senior Medical/regulatory Writer
People
Anthony S. Gibney
Executive Vice President, Chief Business Officer
People
Paul Firuta
Executive Vice President, Chief Operating Officer

Unlock access to complete

Funding Insights of Achillion

Achillion has successfully raised a total of $41M through 1 strategic funding round. The most recent funding activity was a Series C round of $41 million completed in January 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series C — $41.0M
  • First Round

    (28 Jan 2002)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2002 Amount Series C - Achillion Valuation Bear Stearns Companies
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Achillion

Achillion has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alexion, Schroders and GE Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity firm focused on multiple sectors
Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Founded Year Domain Location
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Achillion

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Achillion

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Achillion Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Achillion

Achillion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eiger BioPharmaceuticals, Aligos Therapeutics, AusperBio, Ascentage Pharma and Bluejay Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of antiviral agents against targets in the treatment of hepatitis
domain founded_year HQ Location
Developer of therapies to treat hepatologic diseases and viral infections
domain founded_year HQ Location
Therapies for chronic hepatitis B and infectious diseases are developed.
domain founded_year HQ Location
Small molecule drugs for cancer treatment are developed.
domain founded_year HQ Location
Therapeutics for infectious diseases treatment are developed.
domain founded_year HQ Location
Small-molecule antiviral therapeutics for hepatitis C are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Achillion

When was Achillion founded?

Achillion was founded in 1998 and raised its 1st funding round 4 years after it was founded.

Where is Achillion located?

Achillion is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.

Who is the current CEO of Achillion?

Milind Deshpande is the current CEO of Achillion.

Is Achillion a funded company?

Achillion is a funded company, having raised a total of $41M across 1 funding round to date. The company's 1st funding round was a Series C of $41M, raised on Jan 28, 2002.

What does Achillion do?

Achillion Pharmaceuticals was founded in 1998 and is based in New Haven, United States, within the biotechnology sector. Focus is placed on developing oral drugs for chronic Hepatitis C, with the lead candidate advancing through phase II trials in partnership with Janssen. An additional Factor D inhibitor is under early-stage evaluation for paroxysmal nocturnal hemoglobinuria, dry age-related macular degeneration, and chronic obstructive pulmonary disease.

Who are the top competitors of Achillion?

Achillion's top competitors include Eiger BioPharmaceuticals, AusperBio and Finch Therapeutics.

Who are Achillion's investors?

Achillion has 9 investors. Key investors include Alexion, Schroders, GE Capital, Atlas Venture, and Bear Stearns Companies.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available